(2S,3S,4R,5R)-4-amino-5-(6-aminopurin-9-yl)-2-(methylsulfanylmethyl)oxolan-3-ol | 595608-28-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 2 '，5'-二脱氧核苷
• 英文名称: (2S,3S,4R,5R)-4-amino-5-(6-aminopurin-9-yl)-2-(methylsulfanylmethyl)oxolan-3-ol
• CAS: 595608-28-9
• 化学式: C₁₁H₁₆N₆O₂S
• 分子量: 296.353
• InChiKey: SEFZGNWIAYBDND-HUKYDQBMSA-N

物化性质

• 沸点：
  629.2±65.0 °C(Predicted)
• 密度：
  1.85±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  150
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2S,3S,4R,5R)-4-amino-5-(6-aminopurin-9-yl)-2-(methylsulfanylmethyl)oxolan-3-ol 在 potassium phosphate buffer 、 rh 5'-deoxy-5'-methylthioadenosine phosphorylase 作用下， 生成 、 腺嘌呤
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel human 5′-deoxy-5′-methylthioadenosine phosphorylase (MTAP) substrates

  摘要：

  The structure-based design, chemical synthesis, and biological evaluation of novel MTAP substrates are described. These compounds incorporate various C5'-moieties and are shown to have different k(cat)/K values compared with the natural MTAP substrate (MTA). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.107
• 作为产物：
  描述：

  Trifluoro-methanesulfonic acid (2R,3R,4R,5S)-2-(6-amino-purin-9-yl)-4-(tert-butyl-dimethyl-silanyloxy)-5-methylsulfanylmethyl-tetrahydro-furan-3-yl ester 在 吡啶 、 六甲基磷酰三胺 、 4-二甲氨基吡啶 、 sodium azide 、 tert-butyl-ammonium fluoride 、 氨 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.83h， 生成 (2S,3S,4R,5R)-4-amino-5-(6-aminopurin-9-yl)-2-(methylsulfanylmethyl)oxolan-3-ol
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel human 5′-deoxy-5′-methylthioadenosine phosphorylase (MTAP) substrates

  摘要：

  The structure-based design, chemical synthesis, and biological evaluation of novel MTAP substrates are described. These compounds incorporate various C5'-moieties and are shown to have different k(cat)/K values compared with the natural MTAP substrate (MTA). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.107

文献信息

• Combination therapies for treating methylthioadenosine phosphorylase deficient cells
  申请人：——

  公开号：US20040043959A1

  公开（公告）日：2004-03-04

  The present invention is directed to combination therapies for treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an inhibitor of de novo inosinate synthesis and administering an anti-toxicity agent, wherein the inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase (“GARFT”) and/or aminoinidazolecarboximide ribonucleotide formyltransferase (“AICARFT”), and the anti-toxicity agent is an MTAP substrate (e.g. methylthioadenosine or “MTA”), a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate.

  本发明涉及用于治疗哺乳动物中与甲基硫腺苷磷酸化酶（MTAP）缺乏细胞相关的细胞增殖性疾病的联合疗法。该联合疗法通过给予新生核苷酸合成抑制剂和给予抗毒性剂，选择性地杀死MTAP缺乏细胞，其中，新生核苷酸合成抑制剂是甘氨酰核苷酸甲酰转移酶（“GARFT”）和/或氨基咪唑羧酰核苷酸甲酰转移酶（“AICARFT”）的抑制剂，抗毒性剂是MTAP底物（例如，甲基硫腺苷或“MTA”），MTA的前体，MTA前体的类似物或MTAP底物的前药。
• Design, synthesis, and biological evaluation of novel human 5′-deoxy-5′-methylthioadenosine phosphorylase (MTAP) substrates
  作者：Pei-Pei Kung、Luke R. Zehnder、Jerry J. Meng、Stanley W. Kupchinsky、Donald J. Skalitzky、M. Catherine Johnson、Karen A. Maegley、Anne Ekker、Leslie A. Kuhn、Peter W. Rose、Laura A. Bloom

  DOI：10.1016/j.bmcl.2005.03.107

  日期：2005.6

  The structure-based design, chemical synthesis, and biological evaluation of novel MTAP substrates are described. These compounds incorporate various C5'-moieties and are shown to have different k(cat)/K values compared with the natural MTAP substrate (MTA). (c) 2005 Elsevier Ltd. All rights reserved.